Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2024Biomedicine & PharmacotherapyOpen Access

CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism

View Full Paper
Ask AI
Bookmark
Share

Authors

ZYZhize YeHXHailun XiaJHJinyu Hu

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ye et al. (2024) studied this question.

synapsesocial.com/papers/68e6b291b6db643587633affhttps://doi.org/10.1016/j.biopha.2024.116421
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of the metabolites of tofacitinib in liver microsomes by liquid chromatography combined with high resolution mass spectrometry2021 · 8 citations
  2. 2JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib2021 · 350 citations
  3. 3Functional characterization of CYP2C19 variants in nebivolol 4‐hydroxlation in vitro2017 · 10 citations
  4. 4<p>Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro</p>2019 · 10 citations